Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rhythm Pharmaceuticals Inc.

61.74
+0.40000.65%
Post-market: 61.740.00000.00%19:05 EDT
Volume:628.86K
Turnover:38.70M
Market Cap:3.90B
PE:-14.23
High:61.96
Open:61.11
Low:60.93
Close:61.34
Loading ...

Rhythm Pharmaceuticals: Plan to Initiate New Phase 2 Trial Exploring Setmelanotide in Prader-Willi Syndrome

THOMSON REUTERS
·
10 Jan

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

GlobeNewswire
·
10 Jan

Jefferies starts Rhythm Pharmaceuticals with Buy on obesity potential

TipRanks
·
02 Jan

Jefferies Initiates Rhythm Pharmaceuticals at Buy With $80 Price Target

MT Newswires Live
·
02 Jan

Rhythm Pharmaceuticals initiated with a Buy at Jefferies

TIPRANKS
·
01 Jan

Exploring 3 High Growth Tech Stocks In The United States

Simply Wall St.
·
23 Dec 2024

Rhythm Pharmaceuticals' (NASDAQ:RYTM) investors will be pleased with their incredible 370% return over the last three years

Simply Wall St.
·
23 Dec 2024

Rhythm Pharmaceuticals Price Target Maintained With a $69.00/Share by HC Wainwright & Co.

Dow Jones
·
23 Dec 2024

FDA Expands Rhythm Pharma Obesity Drug Approval to Younger Children

Dow Jones
·
21 Dec 2024

Rhythm Pharmaceuticals Gains FDA Approval for Expanded IMCIVREE Use

MT Newswires Live
·
21 Dec 2024

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

Benzinga
·
21 Dec 2024

Rhythm announces FDA approval of Imcivree for patients as young as 2

TIPRANKS
·
21 Dec 2024

BRIEF-Rhythm Pharmaceuticals Announces FDA Approval Of Imcivree(Setmelanotide) For Patients As Young As 2 Years Old

Reuters
·
21 Dec 2024

Rhythm Pharmaceuticals Announces FDA Approval of Imcivree® (Setmelanotide) for Patients as Young as 2 Years Old

THOMSON REUTERS
·
21 Dec 2024

Top Calls on Wall Street: FedEx, Nike, Affirm, BlackBerry, Merck, Oracle, Reddit, and More

The Fly
·
20 Dec 2024

Oppenheimer Initiates Coverage on Rhythm Pharmaceuticals With Outperform Rating, $76 Price Target

MT Newswires Live
·
20 Dec 2024

Rhythm Pharmaceuticals Is Maintained at Buy by Goldman Sachs

Dow Jones
·
06 Dec 2024

Rhythm Pharmaceuticals Price Target Maintained With a $69.00/Share by HC Wainwright & Co.

Dow Jones
·
04 Dec 2024

Nvidia Chipmaker Taiwan Semi Hits Buy Point Following Bullish Advance

Blockhead
·
03 Dec 2024

Rhythm Pharmaceuticals Says Imcivree Receives Expanded Marketing Authorization in UK

MT Newswires Live
·
03 Dec 2024